Cases
Representative Matters: Mergers & Acquisitions/Securities: Represented Jornaya, a leading provider of consumer behavioral data
intelligence, in its sale to Verisk (Nasdaq: VRSK), a leading data analytics provider, serving customers in insurance, energy
specialized markets,
financial services.
Represented Firmenich Inc., one of the world's largest producers of flavors
fragrances, in connection with its minority investment in a strategic target with an option to acquire the remainder of the company.
Represented Texas Hospice Holdings, LLC, a multi-state hospice facility operator, in connection with the sale of all of its outst
ing equity to Amedisys Inc., a publicly-held hospice company.
Represented Firmenich, Inc., one of the world's largest producers of flavors
fragrances, in connection with its acquisition of Agilex Holdings, Inc., a portfolio company of New York-based private equity firm MidOcean Partners.
Represented Unilife Corp. (Nasdaq: UNIS / ASX: UNS) in connection with its announced effort to seek strategic alternatives, culminating in a strategic collaboration with Amgen Inc. (Nasdaq: AMGN) for Unilife's wearable injectable drug delivery systems to use with Amgen's biologics
other medicines. The deal provides Unilife with investments of up to $90 million from Amgen
restructures Unilife's existing debt with OrbiMed.
Represented the Board of Directors of RCS Capital Corporation (NYSE: RCAP) in the proposed acquisition from VEREIT, Inc. (NYSE: VER) (formerly American Realty Capital Properties, Inc.) of its Private Capital Management Business, Cole Capital, for $700 million.
Representation of the special committee of the board of directors of an NYSE-listed company, backed by a leading private equity sponsor, operating in the consumer services industry in connection with the strategic repurchase of shares from the private equity fund.
Represented Unilife Corp. (NASDAQ: UNIS / ASX: UNS), a developer, manufacturer,
supplier of injectable drug delivery systems, in connection with the sale, through Chapter 11 bankruptcy, of substantially all of its assets to an affiliate of OrbiMed Advisors LLC, a leading investment firm focused on healthcare,
Amgen Inc., (NASDAQ: AMGN), a leading biotechnology company that discovers, develops, manufacturers
delivers human therapeutics for patients with serious illnesses.
Represented Lehigh Gas Partners LP, a wholesale motor fuel distributor now known as CrossAmerica Partners LLP, in connection with its $138 million IPO.
Represented an NYSE MKT-traded company in its agreement to acquire a majority equity interest in a full-service investment bank in exchange for the company's contribution of its $45 million equity interest in its broker-dealer subsidiary.
Represented CTI Group (Holdings) Inc. (OTC: CTIG) in its $22.5 million sale to Enghouse Systems Limited (TSX: ESL) through its wholly-owned subsidiary, New Acquisitions Corporation.
Represented a global fragrance company in a $20 million investment in a strategic partner.
Represented the special committee of the Board of Directors of JAVELIN Mortgage Investment Corp. (NYSE: JMI) in a $900 million merger in which ARMOUR Residential REIT, Inc. (NYSE: ARR) acquired JAVELIN through a cash tender offer followed by an intermediate form merger.
Represented a leading NYSE-traded international REIT in its approximately $900 million acquisition of an NYSE-traded REIT.
Represented a publicly traded manufacturing company in its acquisition of a privately held manufacturing company for approximately $60 million.
Represented a privately held investment firm in its acquisition of a publicly held specialty finance company in an equity exchange.
Represented an NYSE MKT-traded company in a debt-exchange transaction.
Mutual Funds: Independent counsel to the independent trustees of mutual funds
ETFs, including a fund group with assets under management in excess of $55 billion.
Represented the independent trustees of a mutual fund in connection with the launch of a new multi-manager alternative strategies fund
continue to represent the independent trustees in connection with their oversight of such fund.
Represented the independent trustees of a mutual fund in connection with the launch of a new commodities fund
continue to represent the independent trustees in connection with their oversight of such fund.
Represented the independent trustees of an ETF complex in connection with the initial launch of the ETFs in 2008
continue to represent the independent trustees in connection with their oversight of such funds.
Represented the independent trustees of an emerging market ETF complex in connection with the initial launch of the ETFs in 2009
continue to represent the independent trustees in connection with their oversight of such funds.
Represented an NYSE-traded company in a follow-on offering of its common stock for a total capital raise of approximately $50 million.
Securities
general corporate counsel to publicly traded companies, including a Fortune 1000 company.
